In this study, an AAV8-based therapeutic antibody gene transfer model was developed to evaluate a novel humanized anti-CCR4 monoclonal antibody h1567 as a therapeutic drug candidate against CTCL. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.